Hologic Secures Major Patent Victory Against Siemens in European Mammography Technology Dispute
Hologic has announced a significant legal victory in Europe after the Unified Patent Court (UPC) in Germany ruled that Siemens Healthineers infringed a key Hologic patent related to mammography imaging technology. The decision marks one of the most consequential patent enforcement actions in the breast imaging sector in recent years and underscores the importance of intellectual property protection in medical device innovation.
The ruling centers on a patented mammography technology developed by Hologic and incorporated into its Envision platform. According to the court’s findings, Siemens’ MAMMOMAT B.brilliant mammography systems were found to infringe upon Hologic’s European patent rights. As a result, the court ordered extensive remedies, including an immediate injunction, product recall requirements, destruction of affected systems, and financial compensation.
The judgment has implications not only for the companies involved but also for the broader medical imaging industry, where innovation, technological differentiation, and patent protection play critical roles in advancing diagnostic capabilities.
Court Finds Infringement of Hologic’s Mammography Patent
On June 10, 2026, the Unified Patent Court determined that Siemens infringed European Patent EP 2 352 431, a patent covering Hologic’s proprietary focusing technology used in breast imaging applications.
The patent is associated with Hologic’s Envision platform and relates to innovations designed to improve mammography performance and image quality. Hologic has emphasized that the technology represented a significant advancement in breast imaging and was the first innovation of its kind to receive approval from the U.S. Food and Drug Administration.
According to the court’s ruling, Siemens’ latest-generation mammography systems incorporated technology that fell within the scope of Hologic’s patented invention. The decision concluded that Siemens’ activities constituted patent infringement under applicable European intellectual property laws.
The finding represents a major victory for Hologic, which has consistently invested in research and development aimed at advancing breast cancer screening and diagnostic imaging technologies.
Broad Injunction Issued Across Multiple Countries
One of the most notable aspects of the UPC ruling is the breadth of the remedies imposed.
The court ordered an immediate injunction prohibiting Siemens from making, offering, marketing, importing, storing, or using the affected MAMMOMAT B.brilliant systems in Germany, France, and the Netherlands.
Such injunctions are powerful legal tools because they directly restrict the commercial activities associated with products found to infringe patent rights. In this case, the ruling effectively halts Siemens’ ability to continue distributing or selling the affected mammography systems within the specified jurisdictions.
The decision demonstrates the growing influence of the Unified Patent Court, which was established to provide centralized patent enforcement across participating European countries. The UPC’s authority enables patent holders to pursue broader enforcement actions than would traditionally be possible through separate national court proceedings.
For companies operating in highly innovative industries such as medical technology, the ability to obtain multinational injunctions significantly strengthens intellectual property protections.
Mandatory Recall and Product Destruction Ordered
Beyond the injunction, the court imposed additional remedies that further underscore the seriousness of the infringement findings.
The ruling requires Siemens to conduct a mandatory recall of the infringing mammography systems in Germany, France, and the Netherlands. The company must retrieve affected devices from customers and execute a court-ordered destruction process for those systems.
Such remedies are relatively uncommon and typically reserved for cases involving substantial intellectual property violations.
The recall requirement introduces significant operational and financial implications because it extends beyond merely stopping future sales. Siemens must actively remove products already deployed in the marketplace and address the consequences of those removals.
In addition, the company has been ordered to compensate customers for the original purchase price of affected systems and reimburse associated logistics and implementation costs resulting from the recall.
These obligations create a substantial burden that reflects the court’s determination regarding the seriousness of the patent infringement.
Financial Damages and Additional Penalties
The UPC ruling also establishes Hologic’s right to receive monetary compensation related to the infringement.
The court determined that Siemens will be responsible for both retroactive and future damages associated with the unauthorized use of Hologic’s patented technology. The precise financial amount is expected to be determined through subsequent court proceedings.
In addition to damages, Siemens may face further penalties if it fails to comply with the court’s orders. Non-compliance with injunctions, recall requirements, or destruction directives can result in additional legal consequences and financial sanctions.
The combination of injunctive relief, recall obligations, destruction requirements, customer reimbursements, and monetary damages makes the ruling one of the most comprehensive patent enforcement outcomes seen in the medical imaging industry in recent years.
Importance of Innovation in Breast Cancer Screening
The dispute highlights the central role that innovation plays in breast cancer detection technologies.
Mammography remains one of the most important tools available for early breast cancer screening and diagnosis. Advances in imaging quality, image acquisition techniques, patient comfort, and diagnostic accuracy have significantly improved the ability of clinicians to identify cancers at earlier stages.
Medical technology companies invest substantial resources in research, engineering, clinical validation, and regulatory approval processes to develop these innovations. Patents provide legal protection for these investments by granting inventors exclusive rights to their technological developments for a defined period.
Supporters of strong patent protections argue that intellectual property rights encourage continued innovation by allowing companies to recover investments made in research and development. Without such protections, firms may be less willing to commit resources to the development of new technologies.
The Hologic case underscores how patent disputes can emerge when competitors introduce products that allegedly incorporate protected inventions.
Hologic Emphasizes Commitment to Women’s Health
Following the court’s decision, Hologic leadership described the ruling as an important validation of the company’s technological innovation and its broader mission to improve women’s health.
Essex Mitchell, Chief Operating Officer of Hologic, stated that the judgment confirms the originality and strength of the company’s mammography innovations. He emphasized that Hologic’s technologies are designed to support earlier cancer detection, enhance diagnostic confidence, and ultimately improve patient outcomes.
According to Mitchell, protecting intellectual property is not solely a business issue but also a matter of preserving incentives for continued medical innovation. He argued that unauthorized use of patented technologies can undermine investments in future product development and potentially slow the introduction of new tools that healthcare providers rely upon.
The company indicated that it intends to continue defending its intellectual property portfolio while supporting the advancement of breast imaging technologies that improve care for women worldwide.
Growing Role of the Unified Patent Court
The case also illustrates the increasing importance of the Unified Patent Court in Europe’s intellectual property landscape.
Since becoming operational, the UPC has provided patent holders with a centralized mechanism for enforcing rights across multiple European jurisdictions. This approach reduces the complexity of pursuing separate actions in individual countries and can result in broader remedies when infringement is established.
For industries such as medical devices, pharmaceuticals, biotechnology, and advanced technology, the court is rapidly becoming a critical venue for high-stakes patent litigation.
The Hologic-Siemens dispute may serve as a notable example of how the UPC’s authority can influence competitive dynamics and intellectual property strategies across European markets.
The ruling represents a major legal and strategic victory for Hologic and reinforces the value of intellectual property protection in the medical technology sector. The injunction, recall orders, destruction requirements, and damages provisions collectively demonstrate the substantial consequences that can arise from patent infringement findings.
As the case moves into the damages assessment phase, industry observers will closely monitor the financial impact of the decision and its implications for future patent disputes within the healthcare technology market.
For Hologic, the outcome strengthens its position as a leading innovator in breast imaging and women’s health technologies. For the broader industry, the decision serves as a reminder that innovation, regulatory advancement, and intellectual property protection remain deeply interconnected elements of medical technology development.
Ultimately, the case highlights the ongoing importance of safeguarding technological breakthroughs that contribute to earlier detection, improved diagnosis, and better outcomes for patients undergoing breast cancer screening and care.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world.
